New drug SG301 tested in blood cancer patients who have run out of options

NCT ID NCT04684108

Ongoing Disease control Sponsor: Hangzhou Sumgen Biotech Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial is testing a new drug called SG301 in about 61 people with blood cancers like multiple myeloma that have returned or not responded to standard treatments. The main goal is to check the drug's safety and find the best dose to use in future studies. Researchers will also look at how the drug moves through the body and whether it shows any signs of fighting the cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SG301 (a drug given by IV infusion)
What this could lead to: If it works, this could point toward a new treatment option for people with blood cancers that have stopped responding to standard therapies.
What could go wrong: This is a very early Phase 1 trial with only 61 participants, focused mainly on safety and dosing. It is too soon to know if SG301 will be effective, and side effects are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMATOLOGICAL MALIGNANCY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hematopoietic and lymphoid system neoplasm plasma cell myeloma Recurrence refractory plasma cell neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEMATOLOGICAL MALIGNANCY RELAPSED OR REFRACTORY MULTIPLE MYELOMA

Contacts and locations

Show contact details

Locations

Affiliated Beijing Chaoyang Hospital of Capital Medical University

Beijing, Beijing Municipality, 100020, China
Beijing Jishuitan Hostipal

Beijing, Beijing Municipality, 100032, China
Henan Cancer Hospital

Zhengzhou, Henan, 450003, China
Qilu Hospital of Shandong University

Jinan, Shandong, 250063, China
Shanxi Norman Bethune Hospital

Taiyuan, Shanxi, 030032, China
Shengjing Hospital Affiliated to China Medical University

Shenyang, Liaoning, 110136, China
Shenzhen Second People's Hospital

Shenzhen, Guangzhou, 518025, China
The First Affiliated Hospital of Bengbu Medical College

Bengbu, Anhui, 233099, China
The First Affiliated Hospital of China Medical University

Shenyang, Liaoning, 110002, China
The Fourth Affiliated Hospital of Hebei Medical University

Shijiazhuang, Hebei, 050011, China
The Second Affiliated Hospital of Zhejiang University School of Medicine

Hangzhou, Zhejiang, 310003, China
Wuhan University Central South Hospital

Wuhan, Hubei, 430062, China
Wuxi Central Hospital

Wuxi, Jiangsu, 214125, China
Xiangyang Central Hospital

Xiangyang, Hubei, 441021, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.